Orphan drugs and the NHS: should we value rarity?

McCabe, Claxton, Tsuchiya (2005) Orphan drugs and the NHS: should we value rarity? BMJ (IF: 23.6) 331(7523) 1016-9

Abstract

The growing number and costs of drugs for rare diseases are straining healthcare budgets. Decisions on funding these treatments need to be made on a sound basis

Links

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1273462
http://www.ncbi.nlm.nih.gov/pubmed/16254305
http://dx.doi.org/10.1136/bmj.331.7523.1016

Similar articles

Tools

Export to RIS